R. Jove

Oncology · 2000–2014

A researcher in the Science corpus: 14 papers; trusts 12 researchers and is trusted by 12 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 96 citations into it; #145 of 1,698 by trust here, #177 by citations
• Immunology — 66 citations into it; #1,194 of 2,160 by trust here, #650 by citations
• Molecular Biology — 66 citations into it; #11,653 of 17,773 by trust here, #5,864 by citations
• Cancer Research — 41 citations into it
• Pathology and Forensic Medicine — 21 citations into it; #53 of 414 by trust here, #55 by citations

Whom R. Jove trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. James E. Darnell
2. J. Pollard
3. W. Zou
4. Jacqueline F. Bromberg
5. J. Turkson
6. Véronique Baud
7. M. Karin
8. D. Pardoll
9. T. Hirano

Who trusts R. Jove overall

1. Hua Yu
2. Jacqueline F. Bromberg
3. D. Gabrilovich
4. S. Grivennikov
5. Timothy Yeatman

Papers from R. Jove's perspective

Ordered by how strongly the researchers R. Jove trusts endorse each paper. Same corpus, a different order for every researcher.

1. The role of STATs in transcriptional control and their impact on cellular function (Oncogene)
2. Cytokines in cancer pathogenesis and cancer therapy (Nature Reviews. Cancer)
3. Plasmacytoid dendritic cells in immunity (Nature Immunology)
4. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells (Nature Medicine)
5. Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells (Journal of Experimental Medicine)
6. Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells (Journal of Experimental Medicine)
7. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF‐κB (EMBO Journal)
8. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. (Blood)
9. Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma (Science)
10. Tumour-educated macrophages promote tumour progression and metastasis (Nature Reviews. Cancer)

Their papers

• Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis (2002) — 1,244 citations
• STAT proteins: novel molecular targets for cancer drug discovery (2000) — 678 citations
• STATs in oncogenesis (2000) — 1,862 citations
• Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells (2001) — 804 citations
• Revisiting STAT3 signalling in cancer: new and unexpected biological functions (2014) — 2,031 citations
• Persistently-activated Stat3 maintains constitutive NF-κB activity in tumors (2009) — 695 citations
• STATs in cancer inflammation and immunity: a leading role for STAT3 (2009) — 4,361 citations
• Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity (2007) — 754 citations
• Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity (2005) — 1,098 citations
• The STATs of cancer — new molecular targets come of age (2004) — 2,373 citations
• Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells (2004) — 1,211 citations
• Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. (2003) — 620 citations
• Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. (2002) — 1,118 citations
• Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. (2001) — 661 citations